Pharmacokinetics of Tedizolid in an Obese Patient after Bariatric Surgery

Grégoire, Matthieu; Libois, Julia Brochard; Waast, D.; Gaborit, Benjamin; Dauty, Marc; Deslandes, Guillaume; Dailly, Éric; Touchais, S.; Boutoille, David; Grégoire, Nicolas; Couet, William

doi:10.1128/aac.02432-17

Cited by 4 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A pooled retrospective analysis of data from phase I tedizolid studies found no meaningful difference in AUC in healthy obese patients (38 obese (BMI > =30 kg/m 2 ); 136 non‐obese patients) 106 . One case report describes acceptable PK parameters in a 102 kg patient with a history bariatric surgery who received oral tedizolid at routine doses 107 …”

Section: Review Of Specific Antimicrobial Agentsmentioning

confidence: 99%

See 1 more Smart Citation

Comprehensive guidance for antibiotic dosing in obese adults: 2022 update

Meng

Mui

et al. 2023

Pharmacotherapy

View full text Add to dashboard Cite

Drug dosing in obese patients continues to be challenging due to a lack of high-quality evidence to guide dosing recommendations. We first published guidance for antibiotic dosing in obese adults in 2017, in which we critically reviewed articles identified from a broad search strategy to develop dosing recommendations for 35 antimicrobials. In this updated narrative review, we searched Pubmed, Web of Science, and the Cochrane Library using Medical Subject Headings including anti-infectives, specific generic antimicrobial names, obese, pharmacokinetics, and others. We reviewed 393 articles, cross-referenced select cited references, and when applicable, referenced drug databases, package inserts, and clinical trial data to update dosing recommendations for 41 antimicrobials. Most included articles were pharmacokinetic studies, other less frequently included articles were clinical studies (mostly small, retrospective), case reports, and very rarely, guidelines. Pharmacokinetic changes are frequently reported, can be variable, and sometimes conflicting in this population, and do not always translate to a documented difference in clinical outcomes, yet are used to inform dosing strategies. Extended infusions, high doses, and therapeutic drug monitoring remain important strategies to optimize dosing in this population. Additional studies are needed to clinically validate proposed dosing strategies, clarify optimal body size descriptors, dosing weight scalars, and estimation method of renal function in obese patients.

show abstract

Section: Review Of Specific Antimicrobial Agentsmentioning

confidence: 99%

“…106 One case report describes acceptable PK parameters in a 102 kg patient with a history bariatric surgery who received oral tedizolid at routine doses. 107 Summary. Oxazolidinones do not appear to require routine dose adjustments in obesity.…”

Section: Linezolidmentioning

confidence: 99%

Comprehensive guidance for antibiotic dosing in obese adults: 2022 update

Meng

Mui

et al. 2023

Pharmacotherapy

View full text Add to dashboard Cite

show abstract

“…Author (year), study type differences in PK profiles of patients after bariatric surgery compared to the adult population [24].…”

Section: Populationmentioning

confidence: 99%

“…Similarly, no disparity in PK profiles was noted in morbidly obese patients compared to the nonobese subjects [ 23 ]. There were no significant differences in PK profiles of patients after bariatric surgery compared to the adult population [ 24 ].…”

Section: Pharmacokineticsmentioning

confidence: 99%

Pharmacokinetics and Pharmacodynamics of Tedizolid

2022

View full text Add to dashboard Cite

Tedizolid is an oxazolidinone antibiotic with high potency against Gram-positive bacteria and currently prescribed in bacterial skin and skin-structure infections. The aim of the review was to summarize and critically review the key pharmacokinetic and pharmacodynamic aspects of tedizolid. Tedizolid displays linear pharmacokinetics with good tissue penetration. In in vitro susceptibility studies, tedizolid exhibits activity against the majority of Gram-positive bacteria (minimal inhibitory concentration [MIC] of ≤ 0.5 mg/L), is four-fold more potent than linezolid, and has the potential to treat pathogens being less susceptible to linezolid. Area under the unbound concentration-time curve (fAUC) related to MIC (fAUC/MIC) was best correlated with efficacy. In neutropenic mice, fAUC/MIC of ~ 50 and ~ 20 induced bacteriostasis in thigh and pulmonary infection models, respectively, at 24 h. The presence of granulocytes augmented its antibacterial effect. Hence, tedizolid is currently not recommended for immunocompromised patients. Clinical investigations with daily doses of 200 mg for 6 days showed non-inferiority to twice-daily dosing of linezolid 600 mg for 10 days in patients with acute bacterial skin and skin-structure infections. In addition to its use in skin and skin-structure infections, the high pulmonary penetration makes it an attractive option for respiratory infections including Mycobacterium tuberculosis. Resistance against tedizolid is rare yet effective antimicrobial surveillance and defining pharmacokinetic/pharmacodynamic targets for resistance suppression are needed to guide dosing strategies to suppress resistance development.

show abstract